Athenex, Inc. (ATNX) Reaches $16.47 After 4.00% Up Move; Shorts at Walgreen Boots Alliance (WBA) Raised By 3.77%

February 15, 2018 - By Kurt Siggers

Walgreen Boots Alliance Incorporated (NASDAQ:WBA) had an increase of 3.77% in short interest. WBA’s SI was 24.96 million shares in February as released by FINRA. Its up 3.77% from 24.05M shares previously. With 6.19 million avg volume, 4 days are for Walgreen Boots Alliance Incorporated (NASDAQ:WBA)’s short sellers to cover WBA’s short positions. The SI to Walgreen Boots Alliance Incorporated’s float is 2.67%. The stock increased 1.28% or $0.88 during the last trading session, reaching $69.37. About 2.57M shares traded. Walgreens Boots Alliance, Inc. (NASDAQ:WBA) has risen 5.77% since February 15, 2017 and is uptrending. It has underperformed by 10.93% the S&P500.

The stock of Athenex, Inc. (NASDAQ:ATNX) is a huge mover today! The stock increased 5.24% or $0.82 during the last trading session, reaching $16.47. About 241,972 shares traded. Athenex, Inc. (NASDAQ:ATNX) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 8 months positive chart setup for the $1.03 billion company. It was reported on Feb, 15 by Barchart.com. We have $17.13 PT which if reached, will make NASDAQ:ATNX worth $41.04M more.

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer. The company has market cap of $1.03 billion. The Company’s Orascovery product candidates include Oraxol, an oral dosage form, which is in a Phase III trial in metastatic breast cancer for the treatment of advanced gastric cancer; Oratecan, an anticancer agent that is in a Phase 1 study for the treatment of colorectal, lung, ovarian, cervical, pancreatic, upper gastrointestinal, and brain cancer; Oradoxel, an anticancer agent, which is in a Phase 1 clinical study in the treatment of breast, prostate, gastric, head and neck, and lung cancer; and Oratopo, an anticancer for the treatment of cervical, ovarian ,and lung cancer. It currently has negative earnings. The firm also develops KX-01, a compound, which is in Phase 3 study for the treatment of for actinic keratosis; and KX-02 for the treatment of gliomas.

Among 22 analysts covering Walgreens Boots Alliance (NASDAQ:WBA), 14 have Buy rating, 1 Sell and 7 Hold. Therefore 64% are positive. Walgreens Boots Alliance had 52 analyst reports since August 24, 2015 according to SRatingsIntel. Credit Suisse maintained it with “Outperform” rating and $100 target in Monday, November 16 report. The rating was maintained by Jefferies on Tuesday, October 17 with “Buy”. Zacks upgraded Walgreens Boots Alliance, Inc. (NASDAQ:WBA) on Tuesday, September 1 to “Hold” rating. As per Friday, July 22, the company rating was downgraded by Wood. SunTrust maintained the shares of WBA in report on Wednesday, December 20 with “Hold” rating. Jefferies upgraded Walgreens Boots Alliance, Inc. (NASDAQ:WBA) on Monday, October 17 to “Buy” rating. The stock of Walgreens Boots Alliance, Inc. (NASDAQ:WBA) earned “Outperform” rating by Wells Fargo on Monday, October 31. The rating was downgraded by Morgan Stanley to “Equal-Weight” on Friday, October 6. Credit Suisse maintained it with “Outperform” rating and $95 target in Thursday, September 1 report. The rating was maintained by UBS on Wednesday, August 23 with “Buy”.

Walgreens Boots Alliance, Inc. operates as a pharmacy-led health and wellbeing company. The company has market cap of $68.72 billion. It operates through three divisions: Retail Pharmacy USA, Retail Pharmacy International, and Pharmaceutical Wholesale. It has a 19.14 P/E ratio. The Retail Pharmacy USA segment sells prescription drugs and an assortment of general merchandise, including non-prescription drugs, beauty products, photo finishing, seasonal merchandise, greeting cards, and convenience foods through its retail drugstores and convenient care clinics.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: